Trial Profile
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Carboplatin; Gemcitabine
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors XenoPort
- 02 Dec 2023 Planned End Date changed from 30 Nov 2023 to 30 Nov 2024.
- 02 Dec 2023 Planned primary completion date changed from 30 Nov 2023 to 30 Nov 2024.
- 02 Dec 2022 Planned End Date changed from 30 Nov 2022 to 30 Nov 2023.